Xenon Pharmaceuticals Submits Azetukalner Focal-Seizure NDA to FDA; Voluntarily Pauses Enrollment in Major Depressive Disorder Program After Neuropsychiatric Adverse Events, Deferring X-NOVA2 Data to Q1 2027
Xenon Pharmaceuticals (NASDAQ: XENE) announced Thursday September 17, 2026 (syndicated Friday September 18) two updates on azetukalner (small-molecule selective Kv7.2/Kv7.3 potassium-channel opener). First: submission of the New Drug Application to the FDA for focal onset seizures in adults with epilepsy, supported by Phase 3 X-TOLE 2 and X-TOLE 3 registrational data plus long-term open-label extension safety. Second: a voluntary pause on new enrollment in the X-NOVA psychiatry program (major depressive disorder Phase 3) following a small number of neuropsychiatric adverse events under review; existing enrolled participants and all epilepsy studies continue as planned. Xenon deferred X-NOVA2 topline data readout from prior H2 2026 guidance to Q1 2027 pending the safety review. XENE shares fell more than 20% Thursday on the pause, though sell-side analysts (William Blair, Wells Fargo, Guggenheim) maintained conviction in the estimated $2 billion peak epilepsy commercial opportunity. Xenon's Wells Fargo Healthcare Conference presentation on September 8 had preceded the update.